Effects of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin in patients with advanced esophageal cancer

doi:10.11958/20220150

Abstract

Abstract:

Objective To investigate the effect of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin (sE-Cad) in patients with advanced esophageal cancer. Methods A total of 110 patients with advanced esophageal cancer were divided into the combination group (57 cases) and the chemotherapy group (53 cases) according to different therapeutic regimens. Patients in the chemotherapy group were treated with paclitaxel (260 mg/m²) and cisplatin (30 mg/m²) for chemotherapy, while those in the combination group were additionally treated with camrelizumab (200 mg every time, once every 2 weeks) on this basis. The overall curative effect was evaluated after 4-6 cycles of treatment. The serum levels of tumor markers and sE-Cad were detected by enzyme linked immunosorbent assay, and the serum level of miR-21 was detected by real-time fluorescence quantitative polymerase chain reaction. The incidence of adverse reactions during treatment was recorded. Results After treatment, the objective response rate (ORR) and disease control rate (DCR) were higher in the combination group than those in the chemotherapy group (70.18% vs. 45.28% and 91.23% vs. 77.36%, P<0.05). The serum levels of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), squamous cell carcinoma-related antigens (SCC), miR-21 and sE-Cad were significantly lower in the combination group than those in the chemotherapy group (P<0.05). During treatment, the incidence of reactive capillary endothelial proliferation was higher in the combination group than that of the chemotherapy group (P<0.01). Conclusion Camrelizumab combined with chemotherapy has good short-term efficacy in the treatment of advanced esophageal cancer, which can effectively reduce levels of tumor markers, down-regulate serum miR-21 and sE-Cad.

Key words: esophageal neoplasms, drug therapy, combination, antineoplastic combined chemotherapy protocols, molecular targeted therapy, biomarkers, tumor, Camrelizumab, miR-21, soluble E-cadherin

CLC Number:

R735.1

Figures/Tables 6

Tab.1 Comparison of baseline data between the 2 groups

Tab.2 Comparison of general data between the 2 groups

Tab.3 Comparison of overall curative effect between the 2 groups

Tab.4 Comparison of serum tumor marker levels before and after treatment between the 2 groups

Tab.5 Comparison of serum miR-21 and sE-Cad levels before and after treatment between the 2 groups

Tab.6 Comparison of adverse reactions during treatment between the 2 groups

References 23

[1]	HAUGE T, AMDAL C D, FALK R S, et al. Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer-A cohort study[J]. Acta Oncologica, 2020, 18(3):1-7. doi: 10.1080/0284186X.2020.1750694.
[2]	ZHANG D M, LI C S, CHENG N T, et al. CircAGFG1 acts as a sponge of miR-4306 to stimulate esophageal cancer progression by modulating MAPRE2 expression[J]. Acta Histochem, 2021, 123(7):151776. doi: 10.1016/j.acthis.2021.151776.
[3]	BOLLSCHWEILER E, PLUM P, MÖNIG S P, et al. Current and future treatment options for esophageal cancer in the elderly[J]. Expert Opin Pharmacother, 2017, 18(10):1001-1010. doi: 10.1080/14656566.2017.1334764.
[4]	PUETZ K, BOLLSCHWEILER E, SEMRAU R, et al. Neoadjuvant chemoradiation for patients with advanced esophageal cancer-Which response grading system best impacts prognostic discrimination?[J]. Histopathology, 2019, 74(5):731-743. doi: 10.1111/his.13811.
[5]	STILES B M, KAMEL M K, HARRISON S W, et al. Neoadjuvant therapy for locally advanced esophageal cancer should be targeted to tumor histology[J]. Ann Thorac Surg, 2019, 107(1):187-193. doi: 10.1016/j.athoracsur.2018.07.089.
[6]	ZIV G, SALEM B. Pembrolizumab-chemotherapy for advanced oesophageal cancer[J]. Lancet, 2021, 398(10302):726-727. doi: 10.1016/S0140-6736(21)01607-X.
[7]	刘润泽, 常栋, 李博闻. 食管鳞癌免疫治疗的临床进展[J]. 中华肿瘤防治杂志, 2021, 28(13):1028-1032.
	LIU R Z, CHANG D, LI B W. Clinical progress of immunotherapy for esophageal squamous cell carcinoma[J]. Chinese Journal of Cancer Prevention and Treatment, 2021, 28(13):1028-1032. doi: 10.16073/j.cnki.cjcpt.2021.13.11.
[8]	肖勇, 霍前伦, 杨祎明, 等. 卡瑞利珠单抗注射剂联合手术治疗Ⅱ/Ⅲ期食管鳞状细胞癌患者的临床研究[J]. 中国临床药理学杂志, 2021, 37(24):3323-3325.
	XIAO Y, HUO Q L, YANG Y M, et al. Clinical study of camrelizumab injection combined with surgery in the treatment of patients with stage Ⅱ/Ⅲ esophageal squamous cell carcinoma[J]. Chinese Journal of Clinical Pharmacology, 2021, 37(24):3323-3325. doi: 10.13699/j.cnki.1001-6821.2021.24.005.
[9]	LIU L, ZHANG X, ZHOU L H, et al. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer:A case report[J]. Medicine, 2021, 100(35):e27138. doi: 10.1097/MD.0000000000027138.
[10]	梁云微, 连相尧, 党春艳, 等. microRNA-21在食管癌细胞增殖,迁移和凋亡中的作用[J]. 基因组学与应用生物学, 2020, 39(2):845-851.
	LIANG Y W, LIAN X Y, DANG C Y, et al. Roles of microRNA-21 in proliferation,migration and apoptosis of esophageal cancer cells[J]. Genomics and Applied Biology, 2020, 39(2):845-851. doi: 10.13417/j.gab.039.000845.
[11]	NISHIOKA C, IKEZOE T, PAN B, et al. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells[J]. Cancer Sci, 2017, 108(4):685-695. doi: 10.1111/cas.13170.
[12]	项敏敏, 任伟芳, 方忠宏, 等. 卡瑞利珠单抗联用阿帕替尼致药物性肝损伤1例[J]. 中国新药与临床杂志, 2021, 40(7):542-544.
	XIANG M M, REN W F, FANG Z H, et al. A case of drug induced liver injury caused by camrelizumab combined with apatinib[J]. Chinese Journal of New Drugs and Clinical Remedies, 2021, 40(7):542-544. doi: 10.14109/j.cnki.xyylc.2021.07.13.
[13]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. doi: 10.1016/S1359-6349(09)70018-7.
[14]	颜芳, 应明真, 陈龙佩, 等. 白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J]. 中国癌症杂志, 2020, 30(8):632-635.
	YAN F, YING M Z, CHEN L P, et al. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients[J]. China Oncology, 2020, 30(8):632-635. doi: 10.19401/j.cnki.1007-3639.2020.08.011.
[15]	ZENG H M, CHEN W Q, ZHENG R S, et al. Changing cancer survival in China during 2003-15:A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X.
[16]	王文辉, 段旭华, 李浩, 等. 食管动脉化疗栓塞联合卡瑞利珠单抗治疗中晚期食管癌[J]. 中国介入影像与治疗学, 2021, 18(11):699-701.
	WANG W H, DUAN X H, LI H, et al. Chemoembolization of esophageal artery combined with Camrelizumab for treatment of advanced esophageal cancers[J]. Chinese Journal of Interventional Imaging and Therapy, 2021, 18(11):699-701. doi: 10.13929/j.issn.1672-8475.2021.11.014.
[17]	GUZIK K, TOMALA M, MUSZAK D, et al. Development of the inhibitors that target the PD-1/PD-L1 interaction-A brief look at progress on small molecules, peptides and macrocycles[J]. Molecules, 2019, 24(11): E2071. doi: 10.3390/molecules24112071.
[18]	CHEN Y L, CHANG M C, CHENG W F. Metronomic chemotherapy and immunotherapy in cancer treatment[J]. Cancer Lett, 2017, 400(1):282-292. doi: 10.1016/j.canlet.2017.01.040.
[19]	MO H N, HUANG J, XU J C, et al. Safety,anti-tumour activity,and pharmacokinetics of fixed-dose SHR-1210,an anti-PD-1 antibody in advanced solid tumours:A dose-escalation,phase 1 study[J]. Br J Cancer, 2018, 119(5):538-545. doi: 10.1038/s41416-018-0100-3.
[20]	宋琪, 杨淑莉, 郑翠玲, 等. 卡瑞利珠单抗联合白蛋白紫杉醇/洛铂新辅助治疗局部晚期食管癌疗效和安全性Ⅱ期临床观察[J]. 中华转移性肿瘤杂志, 2021, 4(3):218-222.
	SONG Q, YANG S L, ZHENG C L, et al. Efficacy and safety of neoadjuvant therapy with camrelizumab combined with albumin-paclitaxel/lobaplatin for locally advanced esophageal cancer:a phase Ⅱ clinical observation[J]. Chinese Journal of Metastatic Cancer, 2021, 4(3):218-222. doi: 10.3760/cma.j.cn101548-20210219-00024.
[21]	姚丽华, 汪光蓉, 蔡燕, 等. miR-18a和miR-21在食管癌中的表达及其对食管癌的诊断价值[J]. 中华肿瘤杂志, 2019, 41(2):107-111.
	YAO L H, WANG G R, CAI Y, et al. The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer[J]. Chinese Journal of Oncology, 2019, 41(2):107-111. doi: 10.3760/cma.j.issn.0253-3766.2019.02.006.
[22]	KAZUYA T, HIROTAKA K, TOMOHIRO A, et al. Anterior gradient 2 regulates cancer progression in TP53 wildtype esophageal squamous cell carcinoma[J]. Oncol Rep, 2021, 46(6):3898-3409. doi: 10.3892/or.2021.8211.
[23]	高晖, 王海鹏, 李冬雷. 沙利度胺对中晚期食管癌患者调强放化疗效果及血清miR-451、miR-21水平的影响[J]. 山东医药, 2021, 61(5):76-79.
	GAO H, WANG H P, LI D L. Influence of thalidomide on the effects of intensity-modulated radiotherapy and chemotherapy and serum miR-451 and miR-21 levels in patients with advanced esophageal cancer[J]. Shandong Medical Journal, 2021, 61(5):76-79. doi: 10.3969/j.issn.1002-266X.2021.05.021.